Herantis Pharma has signed European Innovation Council (EIC) Accelerator grant agreement
Herantis Pharma Plc, Press release, 12 April 2023 at 08:00 a.m. EEST Herantis will receive €2.5 million grant funding and is eligible for up to €15 million in direct equity investments from the EIC Fund. Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce that the EIC Accelerator grant agreement has been signed. The two-year grant project, named ReTreatPD, will focus on preparations towards a Phase 2 clinical study with HER-096 in Parkinson’s disease including development of biomarkers for monitoring